Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung...

Por Malik, Shakun M., Pazdur, Richard, Abrams, Jeffrey S., Socinski, Mark A., Sause, William T., Harpole, David H., Welch, John J., Korn, Edward L., Ullmann, Claudio Dansky, Hirsch, Fred R.
Publicado em 2014

Noninvasive Risk Stratification of Lung Adenocarcinoma using Quantitative Computed Tomography

Por Raghunath, Sushravya, Maldonado, Fabien, Rajagopalan, Srinivasan, Karwoski, Ronald A., DePew, Zackary S., Bartholmai, Brian J., Peikert, Tobias, Robb, Richard A.
Publicado no J Thorac Oncol (2014)

Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib

Por Gainor, Justin F., Sherman, Carol A., Willoughby, Kathryn, Logan, Jennifer, Kennedy, Elizabeth, Brastianos, Priscilla K., Chi, Andrew S., Shaw, Alice T.
Publicado no J Thorac Oncol (2015)

Racial diversity of actionable mutations in non-small cell lung cancer

Por Bollig-Fischer, Aliccia, Chen, Wei, Gadgeel, Shirish M., Wenzlaff, Angela S., Cote, Michele L., Schwartz, Ann G., Bepler, Gerold
Publicado no J Thorac Oncol (2015)

Disparities in Treatment of Patients with Inoperable Stage I Non-Small Cell Lung Cancer: A Population-Based Analysis

Por Koshy, M., Malik, R., Spiotto, M., Mahmood, U., Weichselbaum, R. R., Sher, D. J.
Publicado no J Thorac Oncol (2015)

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench

Por Suda, Kenichi, Bunn, Paul A., Rivard, Christopher J., Mitsudomi, Tetsuya, Hirsch, Fred R.
Publicado no J Thorac Oncol (2016)

Patients With A Previous History Of Malignancy Undergoing Lung Cancer Screening: Clinical Characteristics And Radiologic Findings

Por Halpenny, Darragh F, Cunningham, Jane D, Long, Niamh M, Sosa, Ramon E, Ginsberg, Michelle S
Publicado no J Thorac Oncol (2016)

A phase 1/2 trial of ruxolitinib and erlotinib in patients with EGFR-mutant lung adenocarcinomas with acquired resistance to erlotinib

Por Yu, Helena A., Perez, Leslie, Chang, Qing, Gao, Sizhi P., Kris, Mark G., Riely, Gregory J., Bromberg, Jacqueline
Publicado no J Thorac Oncol (2016)

Brief Report: A Survey of Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma Work...

Por Shepherd, Annemarie, Riely, Gregory, Detterbeck, Frank, Simone, Charles B., Ahmad, Usman, Huang, James, Korst, Robert, Rajan, Arun, Rimner, Andreas
Publicado no J Thorac Oncol (2016)

Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer

Por Gupta, Arjun, Saltarski, Jessica M., White, Michael A., Scaglioni, Pier P., Gerber, David E.
Publicado no J Thorac Oncol (2017)

EXTENSIVE DISEASE SMALL CELL LUNG CANCER DOSE-RESPONSE RELATIONSHIPS: IMPLICATIONS FOR RESISTANCE MECHANISMS

Por Stewart, David J., Johnson, Constance, Lopez, Adriana, Glisson, Bonnie, Rhee, Jay M., Bekele, B. Nebiyou
Publicado em 2010

Methylation markers for small cell lung cancer in peripheral blood leukocyte DNA

Por Wang, Liang, Aakre, Jeremiah A., Jiang, Ruoxiang, Marks, Randolph S., Wu, Yanhong, Thibodeau, Stephen N., Pankratz, V. Shane, Yang, Ping
Publicado em 2010

Identifying Inhibitors of Epithelial-Mesenchymal Transition by Connectivity-Map Based Systems Approach

Por Reka, Ajaya Kumar, Kuick, Rork, Kurapati, Himabindu, Standiford, Theodore J., Omenn, Gilbert S., Keshamouni, Venkateshwar G.
Publicado em 2011

Phase II study of Belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma

Por Ramalingam, Suresh S., Belani, Chandra P., Ruel, Christopher, Frankel, Paul, Gitlitz, Barbara, Koczywas, Marianna, Espinoza-Delgado, Igor, Gandara, David
Publicado em 2009

NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors

Por Petrini, Iacopo, French, Christopher A., Rajan, Arun, Cameron, Michael J., Jaffe, Elaine, Zucali, Paolo A., Xie, Jianwu, Wang, Yisong, Giaccone, Giuseppe
Publicado em 2012

Proton SBRT For Medically Inoperable Stage I NSCLC

Por Westover, Kenneth D, Seco, Joao, Adams, Judith A, Lanuti, Michael, Choi, Noah C, Engelsman, Martijn, Willers, Henning
Publicado em 2012

Optimization of Response Classification Criteria for Patients with Malignant Pleural Mesothelioma

Por Labby, Zacariah E., Armato, Samuel G., Kindler, Hedy L., Dignam, James J., Hasani, Arman, Nowak, Anna K.
Publicado em 2012

FGFR1 amplification in squamous cell carcinoma of the lung

Por Heist, Rebecca S., Mino-Kenudson, Mari, Sequist, Lecia V., Tammireddy, Swathi, Morrissey, Laura, Christiani, David C., Engelman, Jeffrey A., Iafrate, A. John
Publicado em 2012

Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer

Por Foo, Jasmine, Chmielecki, Juliann, Pao, William, Michor, Franziska
Publicado em 2012

Phase II Study of the HDAC Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (CALGB 30304)

Por Otterson, G.A., Hodgson, L., Pang, H., Vokes, E.E.
Publicado em 2010